Entrepreneur Success Story

News Archive

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes

Naked Biome Entering Clinical Trials to Target Propionibacterium Acnes Naked Biome is developing a probiotic therapy for acne. Instead of killing P. acnes, the QB3@953 startup, would have patients flood their faces with live, healthy strains of bacterium, ensuring the good bacterial will outcompete the bad. Full Scientific American Article

Read more

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment Max Krummel, PhD, Pionyr Co-Founder and Robert E. Smith Endowed Chair in Experimental Pathology, UCSF Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, announced the closing of a […]

Read more

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology

Asilomar Bio and Koch Biological Solutions Agree to Exclusive Commercial License of Leading Yield Enhancement Technology QB3@953 startup, Asilomar has developed a small molecule to improve plant stress response. Koch Biological Solutions, LLC has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a […]

Read more

Logicink announces first product to market: Logicink UV

  On October 19, at Breakout Lab’s Unboxing event, LogicInk, a pioneer in programmable materials, announced its first product to market: LogicInk UV, a wearable that resembles a temporary tattoo and monitors your UV exposure, signaling when it is time to take action to prevent skin damage. The company’s first product, LogicInk UV, targets people concerned about radiation from the sun that can […]

Read more

Siolta Therapeutics wins the Bugs, Drugs, & Beyond QuickFire Challenge

  Johnson & Johnson Innovation, JLABS and the Janssen Human Microbiome Institute (JHMI) launched the second Bugs, Drugs, & Beyond QuickFire Challenge. Taking place in both San Francisco and Cambridge, the Challenge awarded winners with a customized package of support from the JHMI and JLABS, including coaching and $75,000 in funding or entrance to the South San Francisco or Boston JLABS sites, […]

Read more

Indee Labs closed a $1.3M angel round

  Indee Labs closed a $1.3M angel round Indee Labs recently closed a $1.3M angel round and demonstrated functional modification of human primary T-cells with high efficiency (30 to 60%), cell viability (>85%) and recovery (>90%) without T-cell exhaustion or activation. The team also signed its first customer — a clinical-stage biotechnology company developing gene-modified B-cell therapies for rare disease […]

Read more

OneSkin closes $2M Financing to reverse aging skin

  OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne Led by dermatologist Dr. Emma Taylor, the Naked Biome team is developing microbiome-based acne therapeutics. They have now closed a $5 million seed round to get them through clinical proof-of-principle.

Read more

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more
Page 1 of 212

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    09:00-11:00
    03/01/2018
    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter